Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Updates on the epidemiology and risk factors for penile cancer.Transl Androl Urol. 2017; 6: 785-790
- Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003.Cancer. 2008; 113: 2883-2891
- Epidemiology and natural history of penile cancer.Urology. 2010; 76: S2-S6
- Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations.An Bras Dermatol. 2011; 86: 306-317
- Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies.CA Cancer J Clin. 2016; 66: 481-495
- A contemporary review of HPV and penile cancer.Oncology (Williston Park). 2016; 30: 245-249
- Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis.Lancet Oncol. 2019; 20: 145-158
- Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men.J Infect Dis. 2004; 189: 677-685
- Advances in understanding of penile carcinogenesis: the search for actionable targets.Int J Mol Sci. 2017; 18
- Novel targeted therapies for the treatment of penile cancer.Expert Opin Drug Discov. 2014; 9: 959-968
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.Cell. 1990; 63: 1129-1136
- Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.J Pathol. 2003; 201: 109-118
- p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.J Urol. 2002; 168: 81-86
- Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome.J Urol. 2015; 193: 526-531
- Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival.Int J Cancer. 2006; 119: 1078-1081
- Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.Cancer. 2001; 91: 2315-2321
- Human papilloma virus: prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma.Int Braz J Urol. 2013; 39: 542-550
- The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.BMC Cancer. 2015; 15: 220
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.Lancet. 2015; 386: 2078-2088
- Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.J Clin Oncol. 2015; 33: 1543-1550
- Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.Int Immunopharmacol. 2021; 94: 107481
- Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.PloS one. 2011; 6: e17517
- The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases.Hum Pathol. 2013; 44: 2690-2695
- Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy.Cancer Res. 2015; 75: 5219-5227
- Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.J Transl Med. 2013; 11: 161
- First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.BJU Int. 2018; 121: 348-356
- Assessment of PI3K/mTOR/AKT pathway elements to serve as biomarkers and therapeutic targets in penile cancer.Cancers (Basel). 2021; 13: 2323
- Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer.Cancers (Basel). 2022; 14: 1683
- Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma.Clin Cancer Res. 2021; 27: 2560-2570
- The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma.Front Immunol. 2018; 9: 1253
- Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence.Tumour Biol. 2015; 36: 2509-2516
- The immune microenvironment in penile cancer and rationale for immunotherapy.J Clin Med. 2020; 9: 3334
- Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?.J Urol. 2020; 203: 1147-1155
- Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.Ann Oncol. 2016; 27: 1706-1712
- Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.Invest New Drugs. 2021; 39: 1405-1410
- Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to pembrolizumab.Front Oncol. 2020; 10: 615298
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
